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Edited by Jesus AvilaAbstract The abnormal hyperphosphorylation of tau protein is
one of the hallmarks of Alzheimer disease and other tauopathies;
as yet the exact role of various tau kinases in this pathology is
not fully understood. Here, we show that injection of isoprotere-
nol, an activator of cAMP-dependent kinase (PKA), into rat hip-
pocampus bilaterally results in the activation of PKA, calcium/
calmodulin-dependent kinase II and cyclin-dependent kinase-5,
inhibition of protein phosphatase-2A, hyperphosphorylation of
tau at several Alzheimer-like epitopes and a disturbance of spa-
tial memory retention 48 h after the drug injection. These ﬁnd-
ings suggest the involvement of PKA and PKA-mediated
signaling pathway in the Alzheimer-like tau hyperphosphoryla-
tion and memory impairment.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Abnormal hyperphosphorylation of the microtubule associ-
ated protein tau is one of the histopathological hallmarks of
Alzheimers disease (AD) and related tauopathies [1,2]. TheAbbreviations: AD, Alzheimers disease; AKAP79, 79 kDa A-kinase-
anchoring-protein; AP, anterior to posterior; Cb, b catalytic subunit of
PKA; CaMKII, calcium/calmodulin-dependent kinase II; cdk-5,
cyclin-dependent kinase-5; CREB, cAMP-responsive element binding
protein; DAB, diaminobenzidine; DV, dorsal to ventral; FTDP-17,
frontotemporal dementia with Parkinsonism linked to chromosome
17; GSK-3, glycogen synthase kinase-3; IP, isoproterenol; LTP, long-
term potentiation; MAPK, mitogen-activated protein kinase; ML, mid
to lateral; NC, normal control; NS, normal saline; PBS, phosphate-
buﬀered saline; PKA, cAMP-dependent kinase; PKC, protein kinase
C; PP-2A, protein phosphatase-2A; RbII, bII regulatory subunit of
PKA
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in familial frontotemporal dementia with Parkinsonism linked
to chromosome 17 (FTDP-17), a tauopathy, has demonstrated
that abnormalities in this protein can be a primary cause of
neurodegeneration [3,4]. An imbalance of the activities of tau
kinases and tau phosphatases in aﬀected neurons might be
responsible for hyperphosphorylation of tau protein. Recently,
a number of studies have focused on phosphatases related to
tau phosphorylation [5–9]. However, the in vivo information
on the identity and the exact role of protein kinases participat-
ing in the regulation of tau phosphorylation, to date, is limited.
Among several neuronal kinases that have been shown to
hyperphosphorylate tau in vitro are glycogen synthase
kinase-3 (GSK-3), cyclin-dependent kinase-5 (cdk-5), mito-
gen-activated protein kinase (MAPK), calcium/calmodulin-
dependent kinase II (CaMKII), and cAMP-dependent kinase
(PKA) (for review, see [10–12]). However, which of these
kinases are involved in the phosphorylation of tau in vivo is
still not understood. PKA is one of the major microtubule-
associated protein kinases abundant in adult brain, thus being
strategically positioned to inﬂuence tau phosphorylation
[13,14]. PKA is a heterotetramer and comprises two regulatory
subunits and two catalytic units. After activation of adenylyl
cyclase via extracellular signaling events or by speciﬁc activa-
tors such as isoproterenol (IP), ATP is converted into cAMP.
The cAMP then binds to the regulatory subunits releasing the
now-activated catalytic subunits of PKA, which in turn phos-
phorylates substrate proteins. Intracellular cAMP levels and
the subcellular localization of the enzyme determine PKA
function. Analysis of immunohistochemical colocalization
demonstrates that the b catalytic subunit of PKA (Cb), the
bII regulatory subunit of PKA (RbII), and the 79 kDa A-ki-
nase-anchoring-protein (AKAP79) are tightly associated with
the neuroﬁbrillary pathology, positioning PKA to participate
directly in the pathological process of tangle formation seen
in AD [15].
The present study shows that the injection of IP into rat hip-
pocampus bilaterally activates not only PKA but also cdk-5
and CaMKII. Furthermore, it inhibits protein phosphatase
(PP)-2A activity and induces AD-like hyperphosphorylation
of tau at several sites and spatial memory retention deﬁcit in
rats.blished by Elsevier B.V. All rights reserved.
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2.1. Materials
Primary antibodies to tau are listed in Table 1. Secondary antibodies
for Western blot were from Amersham Pharmacia Biotech (Little
Chalfort, Buckinghamshire, England). Detection kit (Histostain-SP)
for immunohistochemistry was from Zymed Laboratory (South San
Francisco, CA). IP obtained from Sigma (St. Louis, MO) was dis-
solved in normal saline (NS) at a stock concentration of 400 mM
and stored at 20 C till used.
2.2. Hippocampus injection
Sprague–Dawley rats (n = 64), male, 3–5 months old, 250–450 g,
were deeply anesthetized intraperitoneally with nembutal or 5% chlo-
ral hydrate and placed in a stereotaxic instrument. 2 ll of IP (10
mM) or NS was slowly injected into the right hippocampus in the
CA1–CA2 area with a 5 ll microsyringe within 30 min using coordi-
nates from the Paxinos atlas as follows [16]: 4.8 mm anterior to pos-
terior (AP) Bregma, 2.2 mm mid to lateral (ML), and 3.0 mm dorsal
to ventral (DV) dura. The needle was left in place 5 min after the
injection before being withdrawn. A second injection was given at
the same coordinates into the opposite, i.e., the left hippocampus.
After behavioral tests, rats were either anesthetized and transcardially
perfused (see below) for immunohistochemical studies or their hippo-
campi were dissected and homogenized at 4 C for biochemical anal-
ysis (see below). Animals employed for biochemical studies at 3, 24,
and 144 h were not subjected to behavioral tests. Rat hippocampi
were quickly dissected out and homogenized in 9 vol of ice cold buf-
fer containing 50 mM Tris–HCl, pH 7.0, 10 mM b-mercaptoethanol,
1.0 mM EDTA, 0.1 mM phenylmethylsulfonyl ﬂuoride, and 2.0 lg/
ml each of aprotinin, leupeptin, and pepstatin A [6]. The homogenate
was centrifuged at 15 000 rpm for 3 min at 4 C and the supernatant
was used for protein kinase and PP assays (see below). For Western
blots (see below), the resulting supernatant was immediately mixed
with the same volume of a cocktail of phosphatase inhibitors contain-
ing 20 mM b-glycerophosphate, 2.0 mM Na3VO4, and 100 mM NaF,
pH 7.0.
2.3. Immunohistochemistry
Isoproterenol-injected (n = 5) and NS-injected (n = 5) rats were
deeply anesthetized and transcardially perfused with 100 ml of 0.01
M phosphate-buﬀered saline (PBS), pH 7.4, and then either perfused
with 400 ml of 4% paraformaldehyde solution or right half of the
brain saved for biochemical studies and the left half was immersion
ﬁxed in the paraformaldehyde solution. The brain was dissected
out and chopped into a 5 · 3 · 3 mm block containing hippocampus.
Each tissue block was postﬁxed in the same 4% paraformaldehyde
solution for 10 h before it was coronally sliced into 40 lm sections
with a Vibratome (LANCER, S100, TPI). Free ﬂoating sections were
blocked with 0.3% H2O2 in absolute methanol for 20 min and non-
speciﬁc sites were blocked with fetal calf serum for 40 min at 37
C. Sections were then incubated overnight at room temperature with
antibodies listed in Table 1. Immunoreaction was visualized by using
biotinylated secondary antibodies (1:200) and avidin-peroxidase con-Table 1
Tau antibodies employed in this study and their properties
Antibody Dilution Typea Speciﬁcityb Phosphorylation sitesc
Tau-1 1:30 000 Mono- P Ser-198/Ser-199/
Ser-202
PHF-1 1:500 Mono- P Ser-396/Ser-404
12e8 1:500 Mono- P Ser-262/Ser-356
M4 1:500 Mono- P Thr-231/Ser-235
92e 1:5000 Poly- P + unP
Other antibodies used: P199, P214, and P262 are all phosphorylation
dependent antibodies, binding to phosphorylated tau at the sites
indicated (1:1000); DM1A (tubulin), 1:2000.
aPoly-, polyclonal; Mono-, monoclonal.
bunP, unphosphorylated epitope; P, phosphorylated epitope.
cNumbered according to the largest isoform of human brain tau,
tau441.jugate (1:200)/diaminobenzidine (DAB) tetrachloride (0.05%) system.
For each primary antibody, 3–5 consecutive sections from each brain
were used.
2.4. Western blots
The phosphorylation of tau was analyzed by Western blots using
10% SDS–PAGE as described originally by Laemmli [17]. The sepa-
rated proteins were transferred on Immobilon-P membrane (Millipore,
Bedford, MA) and probed with several speciﬁc tau antibodies as sum-
marized in Table 1. The blots were developed with peroxidase-conju-
gated secondary antibodies and DAB system.2.5. Protein kinase activity assays
The activities of cdk-5, GSK-3, protein kinase C (PKC) and CaM-
KII were assayed in 25 ll of reaction mixture containing 50 mM
HEPES, pH 7.5, 10 mM MgCl2, 0.06 mg/ml hippocampus extract,
200 lM [c-32P]ATP, and 500 lM cdc2 peptide (Upstate Biotechnol-
ogy) for cdk-5, 50 lM GS2 peptide (Upstate Biotechnology, Ithaca,
NY) for GSK-3, or 20 lM syntide (Sigma) for CaMKII. In the case
of CaMKII, 1 mM CaCl2 as well as 2 lM calmodulin was also in-
cluded [8,9]. The activity of PKA was determined as above except that
the reaction mixture contained 70 mM Na2HPO4/NaH2PO4, pH 6.8,
14 mM MgCl2, 1.4 mM EDTA, 30 lM malantide (Sigma), 200 lM
[c-32P]ATP and 0.06 mg/ll hippocampal extract. The reaction was ini-
tiated by adding [c-32P]ATP. After incubation for 10 min at 30 C, 10
ll reactive mixture was removed and spotted onto phosphocellulose
membrane. The membrane was then washed ﬁve times in 1% phospho-
ric acid to remove non-protein incorporated 32P, dried and counted by
Cerenkov radiation. One unit of activity was deﬁned as the amount of
enzyme that catalyzed the incorporation of 1 nmol 32P/min at 30 C
into the speciﬁc substrate.2.6. PP-2A and PP-1 assays
Phosphorylase-b (2 mg/ml) (Sigma) was phosphorylated into phos-
phorylase-a by incubating it for 10 min at 30 C in 40 mM Tris–HCl,
pH 8.5, 20 mM b-mercaptoethanol, 0.2 mM CaCl2, 15 mM MgCl2,
0.5 mM [c-32P]ATP and 10 lg/ml phosphorylase kinase (Sigma).
The product of 32P-phosphorylase was separated from free ATP on
a Sephadex G-50 column and the protein containing fractions were
collected. The activities of PP-2A and PP-1 towards [32P]-phosphory-
lase-a were assayed by the release of 32P as described previously
[6,18]. The reaction was carried out in 20 ll reaction mixture contain-
ing 50 mM Tris, pH 7.0, 10 mM b-mercaptoethanol, 0.1 mM EDTA,
7.5 mM caﬀeine, 0.2 mg/ml [32P]-phosphorylase-a and 0.06 mg/ml
hippocampal extract. The reaction was started by adding 32P-phos-
phorylase-a. After incubation for 30 min at 30 C, 7 ll of the reac-
tion mixture was spotted on a chromatography paper already
spotted with 10 ll stop solution (4 mM cold ATP in 20% trichloro-
acetic acid [TCA]). The released 32P was separated from the substrate
by ascending chromatography in 5% TCA in 0.2 M NaCl, and the
radioactivity was measured by Cerenkov counting. A PP-1 speciﬁc
inhibitor, inhibitor-1, was included in the assay for PP-2A activity.
PP-1 activity was calculated by subtracting the PP-2A activity from
the total phosphatase activity (PP-1 plus PP-2A) assayed in the ab-
sence of inhibitor-1.2.7. Morris water maze test
The water maze test was conducted as described previously [19,20].
Rats tested in the water maze were extensively handled (2 min every
day for 15 days) prior to the test. Two hours before the test, the ani-
mals were brought to the outer room and kept in cages on shelves to
acclimatize to the environment and to eliminate directional olfactory
and auditory cues. The swimming pool was 60 cm high, 1.2 m in
diameter and was made of stainless steel. The water was heated to
keep the temperature at 26 ± 2 C that was also the room tempera-
ture maintained for the study. The water in the pool was made opa-
que with milk to hide the escape platform. The Plexiglas platform
was 40 cm high, 10 cm in diameter, and its surface was scarred to
help the rats climb on it. The water surface was 18 cm from the
rim of the pool and the inner wall was always carefully wiped to
eliminate any local cues. The rim of the pool was 1.0 m from the
nearest visual cue of red and blue marks. A camera was ﬁxed to
the ceiling of the room, 1.5 m from the water surface. The camera
L. Sun et al. / FEBS Letters 579 (2005) 251–258 253was connected to a digital-tracking device. An IBM computer with
the water maze software was employed to process the tracking infor-
mation.
To exclude the possibility of inﬂuence of surgery itself on spatial
memory retention, we added a normal control (NC) group without
any surgery throughout the test. The submerged platform 2 cm under
water was located at a ﬁxed position throughout training and retention
sessions. A training session consisted of 4 trials altogether (one trial per
quadrant) with a 30 s inter-trial interval, lasting for seven days. On
each trial, rats started from one of the middle of the four quadrants
facing the wall of the pool and ended when they climbed the platform.
The rats were not allowed to search for it more than 60 s, after which
they were guided to the platform. On the eighth day, rats were trained
as usual and their escape latency and swimming path were recorded as
primary protocols. Then, rats were allowed a days rest, before IP or
NS was injected. The retention test was conducted 48 h after surgery,
and all rats were tested and their escape latency and swimming path-
ways were recorded in the same way. No surgical procedure was per-
formed on NC group and the test results of rats in this group were
labeled as NC1 and NC2 as controls to the pre-surgery and post-sur-
gery in IP and NS groups.0
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One-way ANOVA and Post hoc Dunnetts t tests were employed to
compare means of behavioral tests among diﬀerent groups. For quan-
tiﬁcation of Western blots, densitometric scanning was performed and
analyzed with a computer analysis package (NIH Image 1.52 image
analysis software). The phosphatase and kinase activities of the IP-
treated samples were expressed as the percentage of the activities of
the control samples of each set. The students t test was used for anal-
yses of the results of Western blots and enzyme activities. All data were
presented as means ± S.D. of 3–5 independent experiments and ana-
lyzed with the SPSS package 10.0. P values <0.05 were considered sta-
tistically signiﬁcant.0
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Fig. 1. Eﬀect of IP injection on activities of various kinases and
phosphatases. Rat hippocampi were dissected and homogenized into
10% homogenates at 3, 24, 48, and 144 h after IP (n = 5 for each time
period) or vehicle injection (n = 5 for each time period). The activities
of PKA, cdk-5, CaMKII and PP-2A were assayed as described in
Section 2. The phosphatase and kinase activities of the IP-treated
samples were expressed as the percentage of the activities of the control
samples of each set. The activities of PKA, cdk-5 and CaMKII were
increased, while that of PP-2A was decreased. Bars represent
means ± S.D. of 3 independent assays (*P < 0.05).3. Results
In order to activate PKA, we injected IP bilaterally in the
hippocampi of adult rats. The control animals were similarly
treated with NS, the vehicle used for the IP injections. As ex-
pected, the activity of PKA was markedly stimulated in the
hippocampus and was maximum at 48 h post-injection with
IP (n = 5, P < 0.05, Fig. 1). The IP-induced increase in the
PKA activity was seen 24 h but not 3 h post-injection. At
24 and 144 h post-injection, the levels of PKA activity were
similar in the hippocampi of the drug injected animals. Be-
cause of the involvement of PKA in other signaling path-
ways, we also assayed in the drug-treated and control
animals the activities of cdk-5, GSK-3, PKC, CaMKII, PP-
2A and PP-1, whose activities have been strongly implicated
in the abnormal hyperphosphorylation of tau. We found
the activation of cdk-5 at 48 and 144 h, and of CaMKII at
48 h post IP injection. Furthermore, the activity of PP-2A
was found to be decreased at both 48 and 144 h post-injec-
tion with IP (Fig. 1). In contrast, we were unable to detect
any signiﬁcant changes in the activities of GSK-3b, PKC
and PP-1 (data not shown).
The eﬀect of IP injection on the phosphorylation of tau
was examined by Western blots of the hippocampal homoge-
nates from IP injected (n = 5 for each time period) and con-
trol (n = 5 for each time period) animals developed with
various phospho-dependent tau antibodies. The blots were
then scanned and analyzed by computer-assisted densitome-
try for quantiﬁcation. Any changes in the total tau were
examined by developing the Western blots with a phospho-
independent rabbit antibody 92e that recognizes total tau,and normalizing these tau levels by the level of tubulin seen
by Western blots developed with tubulin antibody DM1A.
An increase in the abnormal hyperphosphorylation at Ser-
214 (P214 sites, P < 0.001), Ser-262/356 (12E8 sites,
P < 0.001), and Ser-396/404 (PHF-1 sites, P < 0.05) of tau
in the IP injected animals was observed 24 and 48 h but
not 3 h after the drug injection (Fig. 2). Phosphorylation of
tau at Ser-199 (P199 sites, P < 0.05) decreased 48 h post IP
injection. No signiﬁcant change in the level of total tau was
detected.
To examine the topography of the abnormal hyperphosph-
orylation of tau in the hippocampus of the IP injected animals,
immunohistochemical staining of the drug-injected and the sal-
ine-injected control hippocampi was carried out with several
phospho-dependent antibodies. The results showed an increase
Fig. 2. Western blots of hippocampal homogenates from IP injected and control rats. The blots of homogenates (15 lg/lane) from NC (normal non-
injected; n = 4, lanes 1 and 2), NS (normal saline-injected; n = 5 for each time period, lanes 3–5, 9–11, 15–17) and IP-injected rats (n = 5 for each time
period, lanes 6–8, 12–14, 18–20) were developed with phospho-dependent antibodies to various abnormally phosphorylated sites of tau, and
antibodies to total tau (92e) and to tubulin (DM1A). The blots were scanned by densitometry for quantiﬁcation of changes in phosphorylated
protein. An increase in phosphorylation of tau at P214, P262, 12E8 and PHF-1 epitopes, and a decrease at Ser-199 (P199) were apparent in the IP
injected rats. Each experiment was performed in triplicate.
254 L. Sun et al. / FEBS Letters 579 (2005) 251–258in the phosphorylation of tau at Ser-262/356 (12E8 sites), Ser-
396/404 (PHF-1 sites), Thr-231/Ser-235 (M4 sites) and Ser-198/
199/202 (Tau-1 sites). An especially intense staining was ob-
served with tau antibody 12E8 to Ser-262/356 in animals,
which were sacriﬁced 48 h post IP injection (Fig. 3). The pyra-
midal neurons of CA3/CA4 areas of the IP injected animals
were particularly immunostained. The hyperphosphorylated
tau distributed mainly in the soma of hippocampal pyramidal
neurons, an abnormal distribution of tau similar to that seen in
AD brain. Hyperphosphorylation of tau at the above sites at
48 h decreased and almost disappeared at day 6 and day 14
after injection (data not shown). In addition, the immunostain-
ing with antibodies to pSer-214 showed an overall increase in
the intensity of staining but without diﬀerential staining of
any subregion of the hippocampus (data not shown). The
immunohistochemical staining of tau is known to depend on
its conformational state [1,2]. Thus, in some cases, immunohis-
tochemical staining might not completely parallel with the cor-
responding Western blots data.
Spatial learning and memory is a hippocampus-dependent
process and almost all AD patients develop a spatial learning
and memory deﬁcit. To examine whether the IP-induced acti-
vation of PKA and the abnormal hyperphosphorylation of tauwould associate with a dysfunction of spatial memory, we next
employed the well-established Morris water maze to investi-
gate whether memory retention was altered in the IP-injected
rats. To study positive behavioral alterations accurately and
to study the association of behavioral abnormalities with tau
phosphorylation, we employed the post-training test method.
That is, the retention of spatial memory was determined at
48 h post-injection in rats pre-trained for a week before IP
injection, and the ability of the animals to remember the loca-
tion of the hidden platform in the water maze guided by distal
cues was measured and recorded. Each group of 10 rats was
tested. The IP injected rats were found to have diﬃculty in
picking up the distal cues (Fig. 4A) and their escape latency
to ﬁnd the hidden platform was remarkably prolonged in com-
parison with that observed pre-injection (19.59 ± 6.16 vs.
8.24 ± 1.68 s, P < 0.01). In contrast, the escape latency of NS
and NC groups did not change signiﬁcantly (NS, post-injec-
tion: 12.32 ± 4.64 s vs. pre-injection: 10.05 ± 2.56 s, P = 0.19;
NC, NC2: 9.83 ± 3.10 s vs. NC1: 8.97 ± 1.90 s, P = 0.48). The
escape latency of NS group fell more in post-injection than
NC group but did not reach a statistical signiﬁcance, implicat-
ing that surgical procedure itself had little eﬀect on rats perfor-
mance in water maze. Furthermore, signiﬁcant diﬀerences in
Fig. 4. Eﬀect of IP injection on spatial memory. Rats were trained for
7 days to remember the hidden platform in the water maze. The escape
latency and swimming pathway in search of the platform on the 8th
day was recorded as primary achievement. 48 h after IP (n = 10) or NS
(n = 10) injection, rats were allowed to search for the platform and the
latency, together with the swimming pathway, was recorded to reﬂect
memory retention. The NC group (n = 10) was employed to indicate
the eﬀect of surgical procedure. (A) Bar graph of escape latency to ﬁnd
the hidden platform in Morris water maze. IP-injected rats spent much
longer time to ﬁnd the hidden platform post-injection. All data are
presented as means ± S.D. One-way ANOVA and Post hoc Dunnetts
tests were employed to compare means of escape latency among
diﬀerent groups. \Represents inter-group comparison of IP with NC
and NS (P < 0.01 for both); #represents latency of the same group 48 h
post-injection in comparison to that of pre-injection (P < 0.01). (B)
Swimming paths taken by typical IP injected and control rats from
their starting position at Northeast to the hidden platform at
Southeast in the water maze. a–b, c–d and e–f were from NC, NS
and IP groups, respectively. a, c and e indicate swimming paths from
one typical rat after a seven-day training pre-injection in the case of c
and e. b, d and f indicate swimming paths of the same rats 48 h post-
injection in the case of d and f. Note that IP injected rats lost their
directional bearings and thus employed random search strategy rather
than straight search strategy. NS and NC rats did not change much in
their pathway to ﬁnd the hidden platform.
Fig. 3. Immunohistochemical staining of phosphorylated tau in rat
hippocampus. Vibrotome sections (40 lM thick) cut from rat brain
containing hippocampus two days after NS (n = 5, A, C, E and G) or
IP (n = 5, B, D, F and H) injection. A–B, C–D, E–F and G–H were
immunostained with PHF-1, 12E8, M4 and Tau-1 (for antibodies
speciﬁc, see Table 1), respectively. Note that only slight or no
immunoreaction with PHF1, 12E8 and M4 antibodies was detected in
NS control, while a much stronger immunostaining was seen in IP
injected group, implicating that tau was phosphorylated at PHF-1,
12E8 and M4 sites. In contrast, Tau-1 immunoreaction was weaker in
IP group, indicating that tau was hyperphosphorylated at Tau-1 site.
Magniﬁcation: ·200.
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(P < 0.01) group were observed (Fig. 4A). Recordings of the
swimming paths of pre-injection and post-injection of the same
rat from each group, i.e., IP and NS, and as non-injection con-
trol, the NC animals revealed that the IP-injected animals
swam randomly rather than directly in search of the hidden
platform (Fig. 4Bf). This unsystematical search strategy was
usual in IP group. On the contrary, NS (Fig. 4Bc and Bd)
and NC (Fig. 4Ba and Bb) rats did not change their swimming
path as much. They navigated in a comparatively direct line to
ﬁnd the hidden platform although sometimes thogmotaxical
search strategy was observed. These behavioral studies re-
vealed that the injection of IP into the hippocampus impaired
the retention of spatial memory and spatial recognition in rats.
Notably, in agreement with the time pattern of tau phosphor-
ylation, memory retention deﬁcits disappeared at day 6 after
IP injection (data not shown), suggesting a link between tau
phosphorylation and behavioral abnormalities in this
condition.4. Discussion
In vitro studies have shown that PKA is not only able to
phosphorylate tau at several abnormal sites as seen in AD
brain by itself but also enhances or stimulates the phos-phorylation of tau subsequently by other kinases, such as
GSK-3b and cdk-5 [13,21,22]. By using metabolically compe-
tent rat brain slices, PKA has been reported to regulate tau
phosphorylation in situ [23,24]. In AD brain, PKA-depen-
dent phosphorylation of tau at Ser-214 and Ser-409 was
coincident with the initial appearance of ﬁlamentous aggre-
gates of tau, suggesting that phosphorylation of tau by
256 L. Sun et al. / FEBS Letters 579 (2005) 251–258PKA plays a key role in the early stage of NFT formation
[14]. However, neither the exact role of PKA in phosphory-
lation of tau in vivo nor the eﬀect of PKA activation on spa-
tial memory was previously known. IP is an epinephrine
analog that stimulates b-adrenergic receptors and increases
the intracellular cAMP levels. cAMP then binds to the regu-
latory subunits and activates PKA, which in turn phosphor-
ylates substrate proteins including tau. In the present study,
by injecting IP into rat hippocampus bilaterally we have dis-
covered that IP in vivo not only activates PKA but also cdk-
5 and CaMKII. Furthermore, it inhibits PP-2A activity and
produces abnormal hyperphosphorylation of tau, especially
at Ser-262, and impairs spatial memory retention. These ﬁnd-
ings show that activation of PKA might lead to changes in
the cdk-5, CaMKII and PP-2A signaling and the abnormal
hyperphosphorylation of tau. Thus, it is tempting to specu-
late that PKA activation might be involved in AD type neu-
roﬁbrillary degeneration and the associated deﬁcits in
memory retention. The IP-injected rats might serve as a use-
ful pharmacological animal model to study the eﬀects of
anti-neuroﬁbrillary degeneration drugs for AD and other
tauopathies.
Apart from speciﬁc phosphorylation of tau directly by
PKA, this kinase might co-operate with other neuronal ki-
nases or/and phosphatases building up a regulational net-
work of tau phosphorylation. A particularly important
PKA target protein is DARPP-32, a dopamine and cAMP
regulated phosphoprotein with molecular weight of 32
kDa. Phosphorylation of threonine-34 by PKA allows
DARPP-32 to bind to and inhibit the activity of PP-1 pow-
erfully, which results in a diverse group of PP-1 target pro-
teins remaining phosphorylated [25]. Such targets include ion
channels (some of which are also direct PKA targets) and
transcription factors, for example, cAMP-responsive element
binding protein (CREB). So the DARPP-32-mediated inhibi-
tion of PP-1 acts as an ‘‘accomplice’’ of PKA-induced phos-
phorylation unless phosphate groups are removed from Thr-
34 in DARPP-32, particularly by PP-2B, counteracting the
eﬀects of PKA. To verify if this pathway is also involved
in our experimental system, we determined both the expres-
sion and activity of PP-1. To our surprise, we did not detect
any signiﬁcant change in PP-1 activity although an enhance-
ment in the expression of this phosphatase was detected by
immunohistochemistry and Western blots (data not shown).
Glutamate ligand-gated calcium ion channels and voltage-
gated calcium ion channels are PKA target proteins too.
They are activated when phosphorylated by PKA, thus lead-
ing to an inﬂux of calcium. The elevated calcium intracellu-
larly triggers the activation of a handful of calcium/
calmodulin-dependent protein kinases like CaMKII and pro-
tein phosphatases involved in tau phosphorylation. CaMKII
is another possible key kinase related to the regulation of
cytoskeletal protein phosphorylation, and it is well docu-
mented that this enzyme participates in hippocampus-depen-
dent learning and memory [26,27]. Very well ﬁtted to this
pathway, we found a signiﬁcantly elevated CaMKII activity
during IP-stimulated PKA activation. Previous studies have
shown that dephosphorylation of CaMKII by PP-2A at
Thr286 inhibits the kinase activity [9,28]. Alternatively, stim-
ulation of the CaMKII activity observed in this study might
thus be related to the downregulation of PP-2A. PP-2B is a
calcium/calmodulin-dependent phosphatase, whose mainfunction is counteracting the eﬀects of PKA phosphorylation
in order to regulate and ﬁnetune the phosphorylation stature
of PP-1 target protein [29]. Whether PP-2B activation com-
pensated the IP-induced PKA activation to dephosphorylate
hyperphosphorylated tau and resulted in a signiﬁcant resto-
ration of memory retrieval when rats were tested in the
water maze at 6 day post-injection in our study (data not
shown) remains an exciting question.
The fact that hyperphosphorylation of tau at Ser-198/199/
202, Ser-214, Thr-231/Ser-235, Ser-262/Ser-356, and Ser-396/
Ser-404 sites was associated with behavioral abnormalities
upon PKA activation in adult rats in the present study sug-
gested that tau hyperphosphorylation at these sites was prob-
ably a requisite for impairment in spatial memory retention.
Spatial learning and memory in the water maze is hippocam-
pus-dependent that needs not only the activation of preexist-
ing proteins but also protein synthesis and mRNA
transcriptions [30,31]. A variety of evidence suggests that
PKA and CREB are necessary participants in the formation
of long-term potentiation (LTP), which is considered a poten-
tial cellular mechanism underlying hippocampus-dependent
learning and memory in normal rats [32–34]. Phosphorylation
of Ser-133 by PKA pushes CREB functioning in LTP. In
accordance with a previous study by Taylor et al. [35] who
have shown that PKA activation in prefrontal cortex impairs
working memory performance in rats, the activation of PKA
by IP in rat hippocampi in the present study caused distur-
bance in spatial memory retention, implicating that inappro-
priate activation of PKA might be detrimental to memory in
vivo. In addition, due to the complex network in signaling
pathways, other kinases and phosphatases activated by IP
might also participate in the regulation of behavioral changes
in vivo. Indeed, the roles of cdk-5 and CaMKII activation
and PP-2A inhibition in associative-learning and memory
retention have been suggested in rodents recently [36–38].
Thus, imbalanced activity among kinases and/or phospha-
tases after b-adrenergic receptor activation [39] might collec-
tively disrupt spatial memory. Of course, other mechanisms
except for tau hyperphosphorylation, including the gluta-
mate-mediated excitotoxic neurotransmission and impertur-
bation of calcium homeostasis, might also be involved. The
causal role of PKA upon IP injection in abnormal tau phos-
phorylation and memory retention will require studies
employing inhibitors of PKA or gene manipulation related
to PKA in vivo. In an independent study, we have found that
speciﬁc inhibition of PKA activity by Rp-adenosine 3 0,5 0-cyc-
lic monophosphorothioate triethyl [40] or injection of melato-
nin [41] inhibits the abnormal hyperphosphorylation of tau at
Ser214, PHF-1 and Tau-1 sites.
In conclusion, the present study shows that IP induces, in
addition to PKA, the activation of CaMKII and cdk-5.
Furthermore, it inhibits the activity of PP-2A, and induces
abnormal hyperphosphorylation of tau at Ser-198/199/202,
Thr-231/Ser-235, Ser-214, Ser-262 and Ser-396/404 and
impairment in spatial memory in adult rats. These ﬁndings
might suggest a pivotal upstream role of PKA in a signal
transduction cascade that leads to Alzheimer-like abnormal
hyperphosphorylation of tau and a consequent memory
impairment. Thus, PKA is a promising pharmacological
therapeutic target for AD and other tauopathies that
are characterized by the abnormal hyperphosphorylation of
tau.
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